Duration of dual antiplatelet therapy after drug-eluting stent implantation: A systematic review and meta-analysis of randomized controlled trials

Journal of the American College of Cardiology

Volumn 65, Issue 13, 2015, Pages 1298-1310

  Giustino, Gennaro ^a   Baber, Usman ^a   Sartori, Samantha ^a   Mehran, Roxana ^a   Mastoris, Ioannis ^a   Kini, Annapoorna S ^a   Sharma, Samin K ^a   Pocock, Stuart J ^b   Dangas, George D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bleeding; Myocardial infarction; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; EVEROLIMUS; RAPAMYCIN; ZOTAROLIMUS;

BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; HEART INFARCTION; HUMAN; INCIDENCE; LONGER DUAL ANTIPLATELET THERAPY; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SHORTER DUAL ANTIPLATELET THERAPY; STENT THROMBOSIS; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; CHEMICALLY INDUCED; HEMORRHAGE; META ANALYSIS; MYOCARDIAL INFARCTION; STROKE; THROMBOSIS; TIME;

DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; THROMBOSIS; TIME FACTORS;

EID: 84929884068     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.01.039     Document Type: Article

References (32)

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58: E44-122.
2. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619.
3. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (Paris): 2 year results from a prospective observational study. Lancet 2013;382:1714-22.
4. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409.
5. Holmes DR Jr., Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010;56: 1357-65.
6. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364: 226-35.
7. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371: 2155-66.
8. Stefanini GG, Siontis GC, Cao D, Heg D, Juni P, Windecker S. Short versus long duration of DAPT after DES implantation: A meta-analysis. J Am Coll Cardiol 2014;64:953-4.
9. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: A meta-analysis of randomized trials. Eur Heart J 2012;33:3078-87.
10. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115: 2344-51.
11. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123: 2736-47.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354: 1896-900.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
14. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-8.
15. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA 2013;310:2510-22.
16. Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015 Jan 23 [E-pub ahead of print].
17. Gilard M, Barragan P, Noryani AA, et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 2015;65:777-86.
18. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086-97.
19. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-13.
20. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dualantiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012;125: 2015-26.
21. Collet JP, Silvain J, Barthelemy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): A randomised trial. Lancet 2014;384: 1577-85.
22. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drugeluting stent implantation: A randomized, controlled trial. Circulation 2014;129:304-12.
23. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A prespecified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J 2013;34:909-19.
24. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
25. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
26. Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). J Am Coll Cardiol Intv 2013; 6:914-22.
27. Camenzind E. Final five-year results from the randomized drug-eluting stent trial PROTECT: The Patient-Related Outcomes With Endeavor vs Cypher Stenting Trial. European Society of Cardiology Congress; September 2, 2014; Barcelona, Spain 2014.
28. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41.
29. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-77.
30. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: A pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22.
31. Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: A systematic review and meta-analysis. Lancet 2015; 385:792-8.
32. Camenzind E, Boersma E, Wijns W, et al. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. Eur Heart J 2014;35:1932-48.